CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.
SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
布鲁顿酪氨酸激酶（BTK）抑制剂和BCL2抑制剂获批后，改变了慢性淋巴细胞白血病（CLL）的治疗范式。然而，尽管治疗已有显著改善，患者因获得性耐药突变或不耐受而停药仍很常见。对这两类药物均难治和/或不耐受的“双重暴露/难治”患者，在临床实践中构成重大挑战，亟需新型治疗方法。本文回顾解决这一未满足临床需求的持续努力，包括非共价BTK抑制剂、BTK降解剂、新型BH3模拟物、靶向新抗原的治疗性抗体以及增强免疫细胞功能的疗法的开发。
Regulatory approvals of Bruton tyrosine kinase (BTK) inhibitors and BCL2 inhibitors have transformed the therapeutic paradigm in chronic lymphocytic leukemia (CLL).
However, despite significant improvement, treatment discontinuations due to an acquired resistance mutation or intolerance to these agents are common. Those who are refractory and/or intolerant to both these classes of drugs - the "double exposed/refractory" patients - pose a real challenge in clinical practice and are in dire need of novel therapeutic approaches.
In this manuscript, we review the ongoing efforts addressing this unmet clinical need including the ongoing development of non-covalent BTK inhibitors, BTK degraders, novel BH3-mimetics, therapeutic antibodies targeting novel antigens and immune cell enabling therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
